-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $12

Benzinga·11/06/2026 15:25:32
Listen to the news
Citizens analyst Reni J. Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and raises the price target from $8 to $12.